Bidop, tablets 10 mg 28 pcs

Bidop is a selective beta1-adrenoblocker without intrinsic sympathomimetic activity and has no membrane stabilizing effect. Bidop reduces plasma renin activity, decreases myocardial oxygen demand, reduces HR (at rest and under load).

It has hypotensive, antiarrhythmic and antianginal action.

Blocking in low doses β1-adrenoreceptors of heart, decreases catecholamine-stimulated formation of cAMP from ATP, decreases intracellular flow of calcium ions, produces negative chrono-, dromo-, batmo- and inotropic effects, inhibits conduction and excitability and decreases myocardial contractility.

With increasing dose has a beta2-adrenoblocking effect.

Indications

Arterial hypertension; prevention of angina attacks.

Active ingredient

Composition

1 tablet contains bisoprolol hemifumarate 10 mg

How to take, the dosage

Overly, in the morning, on an empty stomach, without chewing, 2.5-5 mg Bidop once.

If necessary, the dose is increased to 10 mg once daily.

The maximum daily dose is 20 mg daily.

Interaction

Allergens used for immunotherapy or allergen extracts for skin tests increase the risk of severe systemic allergic reactions or anaphylaxis in patients receiving bisoprolol.

Iodine-containing radiopaque drugs for IV administration increase the risk of anaphylactic reactions. Phenytoin when administered by IV, drugs for inhalation general anesthesia (hydrocarbon derivatives) increase the severity of cardiodepressive effects and the likelihood of BP reduction.

Changes the effectiveness of insulin and oral hypoglycemic drugs, masks the symptoms of developing hypoglycemia (tachycardia, BP increase).

Limits clearance of lidocaine and xanthines (except theophylline) and increases their plasma concentrations, especially in patients with initially increased clearance of theophylline under the influence of smoking.

The hypotensive effect is weakened by NSAIDs (sodium ion retention and blockade of prostaglandin synthesis by kidneys), GCS and estrogens (retention of sodium ions).

The cardiac glycosides, methyldopa, reserpine and guanfacine, slow calcium channel blockers (verapamil, diltiazem), amiodarone and other antiarrhythmic medicines increase the risk of developing or worsening bradycardia, AV block, heart failure and heart failure.

Special Instructions

Control of patients taking Bidop should include measurement of HR and BP (at the beginning of treatment – daily, then once every 3-4 months), ECG, determination of blood glucose in diabetic patients (once every 4-5 months).

In elderly patients it is recommended to monitor kidney function (once every 4-5 months).

Contraindications

Side effects

Overdose

Symptoms: arrhythmia, ventricular extrasystole, marked bradycardia, AV-blockade, marked BP decrease, chronic heart failure, cyanosis of finger or palm nails, difficulty breathing, bronchospasm, dizziness, fainting, seizures, hypoglycemia.

Treatment: gastric lavage and administration of adsorptive drugs; symptomatic therapy: if AV blockade has developed – IV 1-2 mg of atropine, epinephrine or placement of a temporary pacemaker; if ventricular extrasystole – lidocaine (Class I A drugs are not used); if BP decreases – the patient should be in Trendelenburg position; if there are no signs of pulmonary edema – IV plasma exchange solutions, if ineffective – injection of epinephrine, dopamine, dobutamine (to maintain chronotropic and inotropic action and eliminate marked BP decrease); in heart failure – cardiac glycosides, diuretics, glucagon; in convulsions – IV diazepam; in bronchospasm – beta2-adrenostimulants inhaled.

Pregnancy use

The use of Bidop in pregnancy and during breastfeeding is possible if the benefit to the mother outweighs the risk of side effects in the fetus and child.

Similarities